Novartis Access: Medicines to treat chronic diseases in lower-income countries

Novartis Access: Medicines to treat chronic diseases in lower-income countries

Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low and middle income countries.

Content from this campaign

Novartis Receives FDA Approval for Egaten® for the Treatment of Fascioliasis, a Neglected Tropical Disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1 Novartis has been donating Egaten to the WHO since 2005, helping to...
Feb 13, 2019 4:35 PM ET
Sandoz Selects Three Finalists for Healthcare Access Challenge (Sandoz HACk) From Over 400 Global Entries
Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges Finalists will participate in a four-day “accelerator event...
Jan 16, 2019 1:20 AM ET
Novartis Access Launches in Latin America
Novartis has signed an agreement with the municipality and the Patronato of Santa Tecla in El Salvador to distribute the Novartis Access portfolio to low-income patients with non-communicable diseases (NCDs) in this community. Beyond medications, the collaboration will also help train health professionals in NCD diagnosis and treatment, and promote education and awareness in the local...
Dec 5, 2018 2:45 PM ET
Sandoz Healthcare Access Challenge (HACk) Returns, Seeking Digital Solutions to Local Healthcare Access Challenges
HOLZKIRCHEN, Germany, October 4, 2018 /3BL Media/ – Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The Sandoz HACk is a global competition that invites entrepreneurs and innovators in the field of digital technology to submit inspirational ideas with...
Oct 4, 2018 9:20 AM ET
GARDP and Novartis Announce Partnership to Reduce Child Deaths From Drug-resistant Infections
Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs) Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives Partnership will leverage knowledge and share...
Sep 27, 2018 2:05 AM ET

Pages